Stocksigma LogoStocksigma Logo

Hemant Surgical Industries Reports Strong H1 FY27 Performance with Significant Revenue and Profit Growth

Hemant Surgical Industries reported a standout H1 ended 30th Sep'26, with consolidated revenue surging 327.59% YoY to ₹27,631.06 lakhs compared to

Hemant Surgical Industries Reports Strong H1 FY27 Performance with Significant Revenue and Profit Growth

Hemant Surgical Industries Ltd · Outcome · 14 Nov 2026, 9:37 pm

Hemant Surgical Industries Reports Strong H1 FY27 Performance with Significant Revenue and Profit Growth Hemant Surgical Industries reported a standout H1 ended 30th Sep'26, with consolidated revenue surging 327.59% YoY to ₹27,631.06 lakhs compared to ₹6,462.01 lakhs in H1 ended 30th Sep'25. Consolidated net profit rose 245.03% YoY to ₹1,883.82 lakhs from ₹545.98 lakhs, driving basic EPS to ₹13.30 from ₹5.15. On a standalone basis, revenue reached ₹27,592.01 lakhs and net profit hit ₹1,911.75 lakhs. The group acquired a 66.66% stake in Lifesenz Cancer Research Labs on 1st Jun'26 for ₹1,999.80 lakhs.

Original exchange filing (PDF)

More announcements from Hemant Surgical Industries Ltd

All Hemant Surgical Industries Ltd announcements